For the quarter ending 2026-03-31, REGN made $3,605,400K in revenue. $661,600K in net income. Net profit margin of 18.35%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | 3,605,400 | 3,884,300 | 3,754,300 | 3,675,600 |
| Research and development | 1,543,500 | 1,626,100 | 1,475,000 | 1,421,700 |
| Acquired in-process research and development | 101,900 | 18,700 | 83,100 | 10,000 |
| Selling, general, and administrative | 647,700 | 775,000 | 657,800 | 634,200 |
| Cost of goods sold, collaboration and contract manufacturing-Product | 373,400 | 318,700 | 281,000 | 275,600 |
| Cost of goods sold, collaboration and contract manufacturing-Collaborationand Contract Manufacturing | 296,000 | 265,900 | 240,600 | 254,600 |
| Other operating (income) expense, net | - | 0 | 10,000 | 0 |
| Total expenses | 2,962,500 | 3,004,400 | 2,727,500 | 2,596,100 |
| Income from operations | 642,900 | 879,900 | 1,026,800 | 1,079,500 |
| Other income (expense), net | 201,200 | 176,000 | 755,800 | 442,800 |
| Interest expense | 12,900 | 12,200 | 19,300 | 3,600 |
| Total other income (expense) | 188,300 | 163,800 | 736,500 | 439,200 |
| Income before income taxes | 831,200 | 1,043,700 | 1,763,300 | 1,518,700 |
| Income tax expense | 104,000 | 199,100 | 303,300 | 127,100 |
| Net income | 727,200 | 844,600 | 1,460,000 | 1,391,600 |
| Unrealized (loss) gain on debt securities | -65,800 | 7,100 | 15,700 | 22,100 |
| Gain (loss) on foreign currency translation | 200 | 1,400 | 800 | 1,300 |
| Comprehensive income | 661,600 | 853,100 | 1,476,500 | 1,415,000 |
| Basic EPS | 6.99 | 8.283 | 14.09 | 13.24 |
| Diluted EPS | 6.75 | 7.943 | 13.62 | 12.81 |
| Basic Average Shares | 104,000,000 | 103,000,000 | 103,600,000 | 105,100,000 |
| Diluted Average Shares | 107,700,000 | 107,400,000 | 107,200,000 | 108,600,000 |
REGENERON PHARMACEUTICALS, INC. (REGN)
REGENERON PHARMACEUTICALS, INC. (REGN)